BTCC / BTCC Square / Global Cryptocurrency /
ImmunityBio Stock Surges 15% on ANKTIVA’s 700% Revenue Growth

ImmunityBio Stock Surges 15% on ANKTIVA’s 700% Revenue Growth

Published:
2026-02-23 17:01:02
11
1
BTCCSquare news:

ImmunityBio, Inc. (IBRX) shares rallied 15.73% to $10.81 following explosive 2025 earnings showing ANKTIVA's net product revenue soaring 700%. The immunotherapy specialist reported $113 million in annual revenue, with Q4 alone delivering a 20% sequential jump. Unit sales of its flagship cancer treatment skyrocketed 750% year-over-year.

Global expansion accelerated with regulatory approvals now spanning 33 countries—including the US, EU, UK, and Saudi Arabia. The Saudi clearance notably expands ANKTIVA's addressable market into lung cancer, with commercial launch expected within 60 days. ImmunityBio's cash position of $242.8 million and patent protection extending beyond 2035 provide runway for its expanding clinical pipeline.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.